- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple myeloma
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 1.2MB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 568KB)
Ixazomib – March 2022
Ixazomib: Capsule 2.3 mg, Capsule 3 mg, Capsule 4 mg; Ninlaro®
Last updated
1 July 2022